GlassScriptPhysician profile
Michael P Truong
NPI 1023096765
$23,245.92
in general payments reported to CMS, 2019-2025
55 companies · $1,718 in 2025
The $1,718 reported for 2025 was more than what a typical Endocrinology, Diabetes & Metabolism provider received nationally (typical 2025 total: $506).
See the full distribution for Endocrinology, Diabetes & Metabolism
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $15K · 2020: $3,203 · 2021: $380 · 2022: $324 · 2023: $1,377 · 2024: $1,423 · 2025: $1,718.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $4,518.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $4,518.38 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Janssen Pharmaceuticals, INC | $12,123.29 | 2019-2020 | |
| Amgen INC. | $1,294.21 | 2019-2025 | Evenity, Prolia, Repatha |
| Lilly USA, LLC | $1,121.80 | 2019-2025 | Mounjaro, Jardiance, Trulicity |
| Medtronic Minimed, INC. | $1,006.69 | 2019-2020 | |
| Novo Nordisk INC | $997.36 | 2019-2025 | Ozempic, Wegovy, Rybelsus |
| Abbott Laboratories | $931.22 | 2019-2025 | Freestyle Libre 3 |
| Abbvie INC. | $833.60 | 2019-2025 | Synthroid, Ubrelvy |
| Sanofi-Aventis U.S. LLC | $604.68 | 2019-2025 | |
| Astrazeneca Pharmaceuticals LP | $517.99 | 2019-2023 | Farxiga |
| Novartis Pharmaceuticals Corporation | $389.71 | 2023-2025 | |
| Dexcom, INC. | $339.63 | 2019-2025 | Dexcom G6 Transmitter |
| Regeneron Healthcare Solutions, INC. | $224.68 | 2019-2025 | Evkeeza |
| Radius Health, INC. | $224.51 | 2019-2025 | Tymlos |
| Corcept Therapeutics | $205.71 | 2019-2025 | Korlym |
| Boehringer Ingelheim Pharmaceuticals, INC. | $197.88 | 2019-2025 | Jardiance |
Show all 55 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Insulet Corporation | $185.80 | 2022-2025 | Omnipod |
| Bayer Healthcare Pharmaceuticals INC. | $175.40 | 2021-2025 | |
| Amarin Pharma, INC. | $164.73 | 2019-2020 | |
| Kyowa Kirin, INC. | $121.79 | 2023-2025 | |
| Nalpropion Pharmaceuticals LLC | $108.47 | 2019 | |
| Merck Sharp & Dohme LLC | $104.51 | 2019 | |
| Recordati_rare_diseases_inc. | $96.29 | 2023-2025 | Isturisa, Signifor Lar |
| Currax Pharmaceuticals LLC | $95.76 | 2019-2024 | Contrave, Nexletol, Nexlizet |
| Ascendis Pharma Endocrinology INC | $91.65 | 2023-2025 | Yorvipath |
| Medtronic, INC. | $80.04 | 2024-2025 | Intellis Adaptivestim, Kyphon Express II Kyphopak Tray, Minimed 780g |
| Antares Pharma, INC. | $73.56 | 2020-2025 | Xyosted |
| Tandem Diabetes Care, INC. | $71.25 | 2024-2025 | T:Slim X2 Insulin Pump With Control-Iq |
| Xeris Pharmaceuticals, INC. | $68.73 | 2024-2025 | Gvoke Hypopen, Recorlev |
| Alexion Pharmaceuticals, INC. | $67.30 | 2019-2024 | Strensiq |
| Amneal Pharmaceuticals LLC | $58.96 | 2019 | |
| Esperion Therapeutics, INC. | $50.36 | 2021-2024 | Nexletol |
| Ipsen Biopharmaceuticals, INC | $47.92 | 2019 | |
| Verity Pharmaceuticals INC. | $46.05 | 2025 | Tlando |
| Kowa Pharmaceuticals America, INC. | $43.88 | 2019 | |
| Ionis Pharmaceuticals, INC. | $41.38 | 2025 | Tryngolza |
| Madrigal Pharmaceuticals | $39.35 | 2025 | Rezdiffra |
| Alvogen INC | $39.15 | 2022-2023 | Teriparatide |
| Cequr Corporation | $34.44 | 2024 | Cequr Simplicity |
| Ibsa Pharma INC. | $32.89 | 2019 | |
| Tolmar, INC. | $29.81 | 2023-2024 | |
| Shire North American Group INC | $27.44 | 2019 | |
| Pfizer INC. | $26.33 | 2019-2021 | |
| Averitas Pharma INC. | $24.94 | 2025 | Qutenza |
| Valeritas, INC. | $21.74 | 2019 | |
| Mimedx Group, INC. | $21.39 | 2025 | |
| Sequel Med Tech, LLC | $20.34 | 2025 | Twiist |
| Glaxosmithkline, LLC. | $18.56 | 2025 | Arexvy, Shingrix |
| Ascend Therapeutics US, LLC | $17.61 | 2021 | |
| Mannkind Corporation | $17.52 | 2024 | |
| Horizon Therapeutics Plc | $14.21 | 2023 | Tepezza |
| Acella Pharmaceuticals, LLC | $14.03 | 2023 | NP Thyroid 60 |
| Eisai INC. | $13.56 | 2019 | |
| Beta Bionics, INC. | $13.24 | 2023 | Ilet Bionic Pancreas |
| Arbor Pharmaceuticals, INC. | $11.40 | 2020 | |
| Travere Therapeutics, INC. | $1.18 | 2020-2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Michael Truong listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.